Mira Kyivska

Injective drops almost 11% after renewed ecosystem support triggers selling pressure

Injective drops almost 11% after renewed ecosystem support triggers selling pressure
Injective slides 10.76% today to $7.11

Injective (INJ) fell 10.76%, with selling pressure intensifying after its Trench Treasury acquired 5% of the $RUNNER token supply as part of ongoing ecosystem initiatives. The down move is limited by indicators of oversold technical conditions and the presence of nearby support, even as current price action remains below short- and medium-term moving averages.

INJ price prediction
24H -1.76%
$7.24
48H -8.55%
$6.74
7D -10.58%
$6.59
1M -12.62%
$6.44
3M -66.35%
$2.48
6M -78.7%
$1.57
12M 18.18%
$8.71
Current price: $7.37 0.52 7.56%
Real-time Data 23:34
Daily range 6.84 Arrow from to Icon 7.74
Weekly range 6.56 Arrow from to Icon 8.44
Loading...

Highlights

  • Injective's Trench Treasury acquired 5% of the $RUNNER token supply to advance ecosystem-focused utility projects.
  • The RunUp team is using native perpetual markets and trading fees to experiment with on-chain treasury management.
  • INJ/USD trades below short- and medium-term moving averages with near-term support at $6.93, resistance at $7.28, and a projected five-day range of $6.6 to $7.62.

Ecosystem expansion drives treasury moves as selling weighs on price

Injective's Trench Treasury acquired 5% of the $RUNNER token supply in a continued effort to support projects that offer utility to the Injective ecosystem. This initiative followed a previous 10% acquisition of NinjaCat's supply and is tied to supporting new value accrual mechanisms and innovative token launch strategies. The RunUp team is leveraging native perpetual markets with trading fees funding on-chain treasury strategies, and Injective’s ecosystem has surpassed 1 billion transactions and over 100 hosted projects, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views the recent 10.76% drop in INJ as a signal of lingering market fragility. He notes the Trench Treasury’s $RUNNER token acquisition did little to offset sustained selling pressure. Technical signals remain mixed, with short-term indicators flashing oversold warnings but longer-term momentum still positive. Kharitonov sees the risk of further downside, especially if INJ loses key support at $6.93, despite strong ecosystem fundamentals. “Unless buyer conviction returns above $7.28, the technical structure suggests continued vulnerability,” Kharitonov warns.
Viktoras Karapetjanc, expert at Traders Union, emphasizes the fundamental strength behind Injective’s ecosystem after surpassing 1 billion transactions and supporting new projects. He sees the Trench Treasury’s strategic acquisition as a positive catalyst for value accrual and future growth. Karapetjanc believes the bullish trend remains intact, especially above the 200-day average. “Injective’s expanding ecosystem and innovative launch models continue to offer fertile ground for further price appreciation,” says Karapetjanc.
Sholanke Dele, market strategist, sees prevailing sentiment as cautious despite recent ecosystem milestones. He notes that broader market volatility and a sharp downside gap reinforce skepticism around near-term rallies. Dele remains wary of persistent selling pressure, especially if technical support at $6.93 fails. “A failure to hold the current range could accelerate losses and dampen short-term sentiment,” Dele comments.
Injective asset chart
Injective price dynamics. Source: TradingView.

Short-term selling prevails as mixed signals temper oversold bounce

INJ/USD is currently trading below both its 20-day and 50-day moving averages ($8.13 and $7.53), while remaining well above the longer-term 200-day average ($5.47). This indicates short- and medium-term pressure from sellers, although the broader trend remains positive with a bullish alignment between the 50-day and 200-day averages. Immediate technical focus sits on the near-term ceiling at $7.28 and near-term floor at $6.93. Momentum indicators point to mixed signals. Moving Average Convergence Divergence (MACD) is in "Strong Buy" territory, but the Average Directional Index (ADX) remains neutral, suggesting the trend is not strongly directional. Relative Strength Index (RSI) is at 50.88 with a "Buy" forecast, while Stochastic RSI is low at 16.66, highlighting oversold conditions. Commodity Channel Index (CCI) reads neutral, and Bull/Bear Power (BBP) at 0.14 signals buyers are slightly ahead, with an oversold warning in place. The Awesome Oscillator also supports renewed buying momentum. The pair has dropped to $7.11, falling $0.86 or 10.76% since the previous close, after opening lower with a downside gap of approximately $0.63 or 7.9%. The price is positioned mid-range for the day, and intraday volatility stands at 7.50%. Overall, the tone is pressured after the open, matching some oversold momentum signals but diverging from the persistent underlying buying strength.

Earlier, analysts noted that Injective was experiencing persistent short- and medium-term weakness despite positive ecosystem developments. The current analysis reinforces these findings, with the market presenting a slightly higher probability of price consolidation between $6.6 and $7.62 in the coming days as oversold signals counter ongoing selling pressure.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.